Caplin Point Laboratories Limited (CAPLIPOINT)
Healthcare | Drug Manufacturers - Specialty & Generic
₹2159.8
0.33% (₹7.2)
Market Overview
| Market Cap | 164170072064 |
| Volume | 75117 |
| 52W High | ₹2641.0 |
| 52W Low | ₹1225.0 |
Key Ratios
| P/E Ratio | 30.779537 |
| EPS | 70.17 |
| Beta | 0.297 |
| Dividend Yield | 0.28% |
Financial Performance
Revenue Growth
0.104%
Profit Margin
0.27681%
ROE
0.20679002%
ROA
0.12295%
Stock Analysis Score: 70/100
Growth Score: 70/100
Key Strengths:
- Excellent profit margins above 15%
- Strong ROE above 15%
- High PE ratio between 25-35
- Low volatility with beta below 1
- Strong operating margins above 15%
Recommendation
Buy - The stock shows good fundamentals with some room for improvement
Detailed Analysis
Growth: 0.1% revenue growth indicates weak business expansion.
Profitability: 27.7% profit margin shows excellent operational efficiency.
Returns: ROE of 20.7% demonstrates strong return on shareholder investment.
Valuation: PE ratio of 30.8x is expensive compared to market averages.
Trading Decision Guide
- Score 80-100: Consider for long-term investment with high conviction
- Score 60-79: Suitable for medium-term investment with regular monitoring
- Score 40-59: Short-term trading opportunities, maintain strict stop-losses
- Score Below 40: High-risk trading only, thorough research essential
Risk Factors
- Market Cap: ₹16417.0Cr
- Beta: 0.30 (Market Volatility)
- 52-Week Range: ₹1225.0 - ₹2641.0
Last Updated: 2025-06-03 05:29:06